{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:56:49Z","timestamp":1782316609974,"version":"3.54.5"},"reference-count":99,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>Antiplatelets and anticoagulants are extensively used in cardiovascular medicine for the prevention and treatment of thrombosis in the venous and arterial circulations. Wide inter-individual variability has been observed in response to antiplatelets and anticoagulants, which triggered researchers to investigate the genetic basis of this variability. Data from extensive pharmacogenetic studies pointed to strong evidence of association between polymorphisms in candidate genes and the pharmacokinetics and pharmacodynamic action and clinical response of the antiplatelets clopidogrel and the anticoagulant warfarin. In this review, we conducted an extensive search on Medline for the time period of 2009\u20132023. We also searched the PharmGKB website for levels of evidence of variant-drug combinations and for drug labels and clinical guidelines. We focus on the pharmacogenetics of novel antiplatelets and anticoagulants while excluding acetylsalicylic acid, warfarin and heparins, and discuss the current knowledge with emphasis on the level of evidence.<\/jats:p>","DOI":"10.1097\/fpc.0000000000000520","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T07:02:24Z","timestamp":1708326144000},"page":"61-72","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacogenetic considerations in therapy with novel antiplatelet and anticoagulant agents"],"prefix":"10.1097","volume":"34","author":[{"given":"Anthony","family":"Yazbeck","sequence":"first","affiliation":[{"name":"Faculty of Medicine, American University of Beirut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Akika","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Awada","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie K.","family":"Zgheib","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"R1-20250808","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/eurheartj\/ehn562","article-title":"Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology.","volume":"30","author":"Kuliczkowski","year":"2009","journal-title":"Eur Heart J"},{"key":"R2-20250808","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1517\/17425255.2015.1068757","article-title":"The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.","volume":"11","author":"Yang","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R4-20250808","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R5-20250808","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-pharmtox-051921-092701","article-title":"Pharmacogenetics of antiplatelet therapy.","volume":"63","author":"Castrichini","year":"2023","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R6-20250808","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/STROKEAHA.122.037717","article-title":"Pharmacogenomics in Stroke and Cardiovascular Disease: State of the Art.","volume":"54","author":"Ross","year":"2023","journal-title":"Stroke"},{"key":"R8-20250808","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine.","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R9-20250808","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.2350","article-title":"An Evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine.","volume":"110","author":"Whirl-Carrillo","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R10-20250808","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/17425255.2017.1338274","article-title":"The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).","volume":"13","author":"O\u2019Connor C","year":"2017","journal-title":"Expert Opin Drug Metab Toxico"},{"key":"R11-20250808","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/gim.0b013e3182329870","article-title":"Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory.","volume":"14","author":"Strom","year":"2012","journal-title":"Genet Med"},{"key":"R12-20250808","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events.","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"R13-20250808","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/gim.2015.171","article-title":"Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians.","volume":"18","author":"Park","year":"2016","journal-title":"Genet Med"},{"key":"R14-20250808","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.gene.2014.12.051","article-title":"Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.","volume":"558","author":"Wang","year":"2015","journal-title":"Gene"},{"key":"R15-20250808","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00228-016-2094-1","article-title":"Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis.","volume":"72","author":"Zhao","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-20250808","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/FPC.0000000000000035","article-title":"The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.","volume":"24","author":"Xie","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"R17-20250808","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2217\/pgs-2017-0070","article-title":"The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy.","volume":"18","author":"Tatarunas","year":"2017","journal-title":"Pharmacogenomics"},{"key":"R18-20250808","doi-asserted-by":"crossref","first-page":"47","DOI":"10.17116\/terarkh201688547-54","article-title":"[The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism].","volume":"88","author":"Bockeria","year":"2016","journal-title":"Ter Arkh"},{"key":"R19-20250808","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4238\/gmr.15028012","article-title":"CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.","volume":"15","author":"Guo","year":"2016","journal-title":"Genet Mol Res"},{"key":"R20-20250808","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.","volume":"5","author":"Brandt","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R21-20250808","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/1440-1681.12390","article-title":"Prevalence of CYP2C19 alleles, pharmacokinetic and pharmacodynamic variation of clopidogrel and prasugrel in Bangladeshi population.","volume":"42","author":"Bin Sayeed","year":"2015","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R22-20250808","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.","volume":"121","author":"Sibbing","year":"2010","journal-title":"Circulation"},{"key":"R23-20250808","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/cpt.2039","article-title":"Impact of the CYP2C19 17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.","volume":"109","author":"Lee","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R24-20250808","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/cpt.1911","article-title":"Genomewide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the international clopidogrel pharmacogenomics consortium.","volume":"108","author":"Verma","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"R25-20250808","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2459\/JCM.0000000000000738","article-title":"Clopidogrel pharmacogenetics: associations between genotype and stent thrombosis risk in patients with stent placement.","volume":"20","author":"Ferrari","year":"2019","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"R26-20250808","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e32835aa8a2","article-title":"The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.","volume":"23","author":"Lewis","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"R27-20250808","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cpt.101","article-title":"Carboxylesterase 1 c428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans.","volume":"97","author":"Tarkiainen","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R28-20250808","first-page":"74","article-title":"[Association of ITGB3, P2RY12, and CYP2C19 gene polymorphisms with platelet functional activity in patients with coronary heart disease during dual antiplatelet therapy].","volume":"89","author":"Muslimova","year":"2017","journal-title":"Ter Arkh"},{"key":"R29-20250808","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.mbc.0000164429.21040.0a","article-title":"P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose.","volume":"16","author":"von Beckerath","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R30-20250808","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.thromres.2006.02.006","article-title":"Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel.","volume":"119","author":"Lev","year":"2007","journal-title":"Thromb Res"},{"key":"R31-20250808","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.thromres.2005.03.001","article-title":"Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.","volume":"116","author":"Angiolillo","year":"2005","journal-title":"Thromb Res"},{"key":"R32-20250808","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/FPC.0b013e328333dafe","article-title":"Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.","volume":"20","author":"Harmsze","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"R33-20250808","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.thromres.2007.01.012","article-title":"Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.","volume":"120","author":"Cuisset","year":"2007","journal-title":"Thromb Res"},{"key":"R34-20250808","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2217\/pgs.12.24","article-title":"CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.","volume":"13","author":"Chan","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R35-20250808","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.thromres.2011.12.038","article-title":"Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade.","volume":"130","author":"Bonello","year":"2012","journal-title":"Thromb Res"},{"key":"R36-20250808","doi-asserted-by":"crossref","first-page":"e6553","DOI":"10.1097\/MD.0000000000006553","article-title":"Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome.","volume":"96","author":"Li","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"R37-20250808","doi-asserted-by":"crossref","first-page":"e007019","DOI":"10.1161\/CIRCINTERVENTIONS.118.007019","article-title":"Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel.","volume":"12","author":"Xu","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"R38-20250808","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"R39-20250808","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2125.2011.04049.x","article-title":"Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.","volume":"73","author":"Kelly","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"R40-20250808","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/eurheartj\/ehp157","article-title":"Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.","volume":"30","author":"Varenhorst","year":"2009","journal-title":"Eur Heart J"},{"key":"R41-20250808","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/cpt.1177","article-title":"CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel.","volume":"105","author":"Holmberg","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R42-20250808","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.amjcard.2012.12.013","article-title":"Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.","volume":"111","author":"Grosdidier","year":"2013","journal-title":"Am J Cardiol"},{"key":"R43-20250808","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jcin.2012.07.015","article-title":"CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome.","volume":"5","author":"Cuisset","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"R45-20250808","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"R46-20250808","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.thromres.2019.01.017","article-title":"Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.","volume":"177","author":"Kimmelstiel","year":"2019","journal-title":"Thromb Res"},{"key":"R47-20250808","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2018.11.013","article-title":"Candidate gene and pathway analyses identifying genetic variations associated with prasugrel pharmacokinetics and pharmacodynamics.","volume":"173","author":"Liu","year":"2019","journal-title":"Thromb Res"},{"key":"R48-20250808","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"R49-20250808","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","article-title":"Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.","volume":"32","author":"Becker","year":"2011","journal-title":"Eur Heart J"},{"key":"R50-20250808","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"R51-20250808","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ijcard.2015.06.016","article-title":"A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window.","volume":"197","author":"Malhotra","year":"2015","journal-title":"Int J Cardiol"},{"key":"R52-20250808","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/eurheartj\/ehv116","article-title":"Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.","volume":"36","author":"Varenhorst","year":"2015","journal-title":"Eur Heart J"},{"key":"R53-20250808","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3389\/fphar.2019.00209","article-title":"Pharmacokinetic and pharmacogenetic factors contributing to platelet function recovery after single dose of ticagrelor in healthy subjects.","volume":"10","author":"Zhu","year":"2019","journal-title":"Front Pharmacol"},{"key":"R54-20250808","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1248\/bpb.b16-00686","article-title":"No Effect of SLCO1B1 and CYP3A4\/5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Male Subjects.","volume":"40","author":"Li","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"R55-20250808","first-page":"176","article-title":"Effect of CYP3A4(*)1G and CYP3A5(*)3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects.","volume":"8","author":"Liu","year":"2017","journal-title":"Front Pharmacol"},{"key":"R56-20250808","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1080\/00498254.2016.1271962","article-title":"Association of PEAR1 rs12041331 polymorphism and pharmacodynamics of ticagrelor in healthy Chinese volunteers.","volume":"47","author":"Li","year":"2017","journal-title":"Xenobiotica"},{"key":"R57-20250808","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2017.12.035","article-title":"Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients.","volume":"129","author":"Nardin","year":"2018","journal-title":"Pharmacol Res"},{"key":"R58-20250808","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1074248413511693","article-title":"Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1.","volume":"19","author":"Armstrong","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R59-20250808","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1074248411410883","article-title":"Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model.","volume":"17","author":"van Giezen","year":"2012","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R60-20250808","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/jth.12360","article-title":"Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism.","volume":"11","author":"Nylander","year":"2013","journal-title":"J Thromb Haemost"},{"key":"R61-20250808","doi-asserted-by":"crossref","first-page":"24680","DOI":"10.1074\/jbc.M413411200","article-title":"Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation.","volume":"280","author":"Nanda","year":"2005","journal-title":"J Biol Chem"},{"key":"R62-20250808","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MBC.0000000000000053","article-title":"The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy.","volume":"25","author":"Tatarunas","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R64-20250808","first-page":"192","article-title":"Chemical structures and mode of action of intravenous glycoprotein IIb\/IIIa receptor blockers: A review.","volume":"13","author":"Hashemzadeh","year":"2008","journal-title":"Exp Clin Cardiol"},{"key":"R66-20250808","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1517\/17425255.1.4.727","article-title":"Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.","volume":"1","author":"Jennings","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R69-20250808","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJM199604253341703","article-title":"A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis.","volume":"334","author":"Weiss","year":"1996","journal-title":"N Engl J Med"},{"key":"R70-20250808","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00008571-200210000-00011","article-title":"No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb\/IIIa inhibitors.","volume":"12","author":"Weber","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R71-20250808","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/09537100701326739","article-title":"Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.","volume":"18","author":"Sirotkina","year":"2007","journal-title":"Platelets"},{"key":"R72-20250808","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(02)02391-9","article-title":"Antagonists of platelet fibrinogen receptor are less effective in carriers of Pl(A2) polymorphism of beta(3) integrin.","volume":"454","author":"Rozalski","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"R73-20250808","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1161\/01.CIR.101.9.1013","article-title":"Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.","volume":"101","author":"Michelson","year":"2000","journal-title":"Circulation"},{"key":"R74-20250808","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood.V98.12.3256","article-title":"Genetic variation in glycoprotein IIb\/IIIa (GPIIb\/IIIa) as a determinant of the responses to an oral GPIIb\/IIIa antagonist in patients with unstable coronary syndromes.","volume":"98","author":"O\u2019Connor","year":"2001","journal-title":"Blood"},{"key":"R75-20250808","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1067\/mhj.2002.119763","article-title":"Reduced inhibition by abciximab in platelets with the PlA2 polymorphism.","volume":"143","author":"Wheeler","year":"2002","journal-title":"Am Heart J"},{"key":"R76-20250808","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/MBC.0b013e32835d546e","article-title":"PlA(1)\/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.","volume":"24","author":"Verdoia","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R77-20250808","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1160\/TH03-06-0341","article-title":"PlA polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction.","volume":"91","author":"Gorchakova","year":"2004","journal-title":"Thromb Haemost"},{"key":"R78-20250808","first-page":"564","article-title":"Vorapaxar: targeting a novel antiplatelet pathway.","volume":"36","author":"Abdulsattar","year":"2011","journal-title":"P T"},{"key":"R79-20250808","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1111\/jth.14318","article-title":"The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y12 inhibition.","volume":"16","author":"Whitley","year":"2018","journal-title":"J Thromb Haemost"},{"key":"R80-20250808","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/blood-2014-04-572479","article-title":"Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race.","volume":"124","author":"Edelstein","year":"2014","journal-title":"Blood"},{"key":"R81-20250808","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1161\/ATVBAHA.115.307102","article-title":"Protease-activated receptor 4 variant ptyr157cys reduces platelet functional responses and alters receptor trafficking.","volume":"36","author":"Norman","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R82-20250808","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bcmd.2018.07.004","article-title":"Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: analysis from the TRACER trial.","volume":"72","author":"Tricoci","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"R83-20250808","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/17425255.2019.1623878","article-title":"Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation.","volume":"15","author":"Kampouraki","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R84-20250808","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R85-20250808","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.112.001233","article-title":"Genetic determinants of dabigatran plasma levels and their relation to bleeding.","volume":"127","author":"Pare","year":"2013","journal-title":"Circulation"},{"key":"R86-20250808","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2016.05.025","article-title":"Pharmacogenetics of dabigatran etexilate interindividual variability.","volume":"144","author":"Dimatteo","year":"2016","journal-title":"Thromb Res"},{"key":"R87-20250808","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40268-014-0045-9","article-title":"Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C.","volume":"14","author":"Chin","year":"2014","journal-title":"Drugs R D"},{"key":"R88-20250808","first-page":"127","article-title":"The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty.","volume":"11","author":"Sychev","year":"2018","journal-title":"Pharmgenomics Pers Med"},{"key":"R89-20250808","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jth.13577","article-title":"Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin.","volume":"15","author":"Gouin-Thibault","year":"2017","journal-title":"J Thromb Haemost"},{"key":"R90-20250808","first-page":"05","article-title":"Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease.","volume":"0","author":"Sychev","year":"2020","journal-title":"Drug Metab Pers Ther"},{"key":"R91-20250808","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/bcp.14646","article-title":"The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation.","volume":"87","author":"Ji","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R92-20250808","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/genes14061192","article-title":"The distribution of the genotypes of ABCB1 and CES1 polymorphisms in Kazakhstani patients with atrial fibrillation treated with DOAC.","volume":"14","author":"Abdrakhmanov","year":"2023","journal-title":"Genes"},{"key":"R93-20250808","doi-asserted-by":"crossref","first-page":"639854","DOI":"10.3389\/fphar.2021.639854","article-title":"Influence of ABCB1 gene polymorphism on rivaroxaban blood concentration and hemorrhagic events in patients with atrial fibrillation.","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"R94-20250808","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/FPC.0000000000000483","article-title":"Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice.","volume":"32","author":"Sychev","year":"2022","journal-title":"Pharmacogenetics and Genomics"},{"key":"R95-20250808","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12959-018-0183-3","article-title":"Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study.","volume":"16","author":"Sennesael","year":"2018","journal-title":"Thromb J"},{"key":"R96-20250808","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/cpt.2316","article-title":"Pharmacogenetics of bleeding and thromboembolic events in direct oral anticoagulant users.","volume":"110","author":"Lahteenmaki","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R97-20250808","doi-asserted-by":"crossref","first-page":"115058","DOI":"10.1016\/j.biopha.2023.115058","article-title":"NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers.","volume":"165","author":"Villapalos-Garcia","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"R99-20250808","doi-asserted-by":"crossref","first-page":"982955","DOI":"10.3389\/fgene.2022.982955","article-title":"Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events.","volume":"13","author":"Attelind","year":"2022","journal-title":"Front Genet"},{"key":"R100-20250808","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11239-019-01962-2","article-title":"Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.","volume":"49","author":"Gulilat","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"R101-20250808","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/FPC.0000000000000294","article-title":"Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.","volume":"27","author":"Ueshima","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"R102-20250808","first-page":"43","article-title":"Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke.","volume":"11","author":"Kryukov","year":"2018","journal-title":"Pharmgenomics Pers Med"},{"key":"R103-20250808","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.thromres.2016.07.005","article-title":"ABCB1 SNP rs4148738 modulation of apixaban interindividual variability.","volume":"145","author":"Dimatteo","year":"2016","journal-title":"Thromb Res"},{"key":"R105-20250808","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R106-20250808","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/tpj.2016.82","article-title":"An integrated pharmacokinetic\/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure.","volume":"18","author":"Vandell","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"R108-20250808","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4321\/S1886-36552014000300007","article-title":"Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention.","volume":"12","author":"Patel","year":"2014","journal-title":"Pharm Pract (Granada)"},{"key":"R109-20250808","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40258-017-0317-y","article-title":"Cost effectiveness of genotype-guided warfarin dosing in patients with mechanical heart valve replacement under the fee-for-service system.","volume":"15","author":"Kim","year":"2017","journal-title":"Appl Health Econ Health Policy"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T12:01:27Z","timestamp":1754654487000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000520","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,19]]}}}